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ABSTRACT
Genome-wide association studies (GWAS) have identified SNPs linked with lung cancer risk. Our 
aim was to discover the genes, non-coding RNAs, and regulatory elements within GWAS-identified 
risk regions that are deregulated in non-small cell lung carcinoma (NSCLC) to identify novel, 
clinically targetable genes and mechanisms in carcinogenesis. A targeted bisulphite-sequencing 
approach was used to comprehensively investigate DNA methylation changes occurring within 
lung cancer risk regions in 17 NSCLC and adjacent normal tissue pairs. We report differences in 
differentially methylated regions between adenocarcinoma and squamous cell carcinoma. Among 
the minimal regions found to be differentially methylated in at least 50% of the patients, 7 
candidates were replicated in 2 independent cohorts (n = 27 and n = 87) and the potential of 6 as 
methylation-dependent regulatory elements was confirmed by functional assays. This study 
contributes to understanding the pathways implicated in lung cancer initiation and progression, 
and provides new potential targets for cancer treatment.
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Lung cancer is the major cause of cancer-related 
deaths in both men and women worldwide [1]. 
GWAS and meta-analyses have reported 
a number of SNPs associated with lung cancer 
risk for adenocarcinoma (AD) and squamous cell 
carcinoma (SCC), the two major non-small cell 
lung cancer subtypes [2–8]. Some risk SNPs for 
lung cancer have been reported in multiple inde-
pendent studies and in populations with different 
origins (e.g., 5p15.33, 6p21.33, 8p11, 15q25.1 and 
19q13.2) while others seem to be population spe-
cific (e.g., 11q22, 13q12, 18p11 and 21q22). Most 
of these regions contain dozens to hundreds of 
SNPs that are highly associated with lung cancer 
risk, and few of the variants have known mechan-
isms by which they affect lung cancer develop-
ment. This shows that we are still far from 
understanding the role of risk SNPs and their 
contribution to the disease and the complexity of 
the risk regions and the genes and regulatory ele-
ments that are located therein.
Aside from genomic alterations, epigenetic 
changes also have an important role in complex 
diseases such as cancer. DNA methylation is 
usually interrogated as a surrogate marker for epi-
genetic alterations. Recently, a few genome-wide 
studies have been addressed at evaluating DNA 
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methylation changes in lung cancer. The Cancer 
Genome Atlas Research Network (TCGA) per-
formed a comprehensive characterization of AD 
and SCC subtypes, including a genome-wide 
CpG methylation analysis using Infinium 
HumanMethylation450 BeadChip array 
(Illumina450K) [9,10]. Their results supported 
a high degree of heterogeneity present in lung 
cancer comprising a large number of mutations, 
copy number alterations and differences in methy-
lation and gene expression levels within and 
between cancer subtypes.
The availability of SNPs and Illumina450K data 
on the same normal lung tissue samples was used 
by Shi et al. to investigate the effect of genetic 
variation on DNA methylation by analysing 
methylation quantitative trait loci (meQTL) [11]. 
The authors identified cis-meQTLs for 34,304 
CpG Illumina probes and 585 trans-meQTLs, 
including inter- and intrachromosomal associa-
tions. Heyn et al. combined Illumina450K and 
Genome-Wide Human SNP Array 6.0 
(Affymetrix) pan-cancer data from TCGA to iden-
tify genome-wide associations between methyla-
tion and risk genetic variants for the most 
common solid tumour entities [12]. Investigating 
cis-meQTLs for 109 GWAS associated SNPs in 13 
different cancer types, they found cis-meQTLs in 
the promoter region of TP63 and TERT for 
rs10937405 and rs2736100, respectively, in lung 
adenocarcinoma samples. These studies demon-
strate the importance of studying the epigenome 
to help us to understand lung carcinogenesis.
Most of the recent studies conducted to eval-
uate the effect of genetic variation on the 
methylome make use of Illumina450K arrays 
that are commonly used as a tool for genome- 
wide screening of DNA methylation on a large 
number of samples; however, the resolution of 
the arrays is limited and restricted to the pre-
designed regions. Using quantitative methyla-
tion analysis targeted to specific genomic 
regions, Scherf et al. demonstrated that pre-
viously reported lung cancer risk SNPs on 
15q25 were associated with DNA methylation 
levels in the promoter of CHRNB4. 
Furthermore, CHRNB4 promoter hypomethyla-
tion in the tumours was linked with gene over-
expression [13], and in vitro knock-down of the 
gene reduced cell proliferation and the capacity 
for colony formation. In addition, Jones et al. 
reported a particular CpG site (cg17028067) for 
which methylation is associated with plasma 
levels of Lipoprotein(a) [14]. Further analysis 
revealed the causative effect as a low frequency 
G/A SNP, rs76735376 within the cg17028067, 
which affects the methylation status of the 
CpG, thus altering enhancer activity. These 
types of studies demonstrate the clear intercon-
nection between the genome and the epigenome 
and emphasize the necessity of studying lung 
cancer risk regions in detail in order to deci-
pher the link between risk SNPs and the causal 
changes affecting disease susceptibility or 
progression.
Our study aims to contribute to the understand-
ing of lung cancer by exploring DNA methylation 
patterns at the disease-implicated loci defined by 
GWAS. We used a targeted bisulphite sequencing 
approach in order to perform a comprehensive 
methylome characterization of the lung cancer 
risk regions. This is the first time that DNA 
methylation changes are analysed in lung cancer 
risk regions in a comprehensive manner, with 
single CpG resolution and a high power to detect 
deregulated regions in lung cancer.
Material and methods
Sample collection
All subjects included in the discovery cohort and 
replication cohort 1 were male smokers with 
stage I lung cancer. Replication cohort 2 was 
composed of a higher number of subjects 
including men and women with stages ranging 
from IA to IIIA. Tumour histology was classified 
according to the 3rd edition of the World Health 
Organization classification system [15]. All 
cohorts comprised subjects with lung adenocar-
cinoma (AD) or lung squamous cell carcinoma 
(SCC). DNA samples from fresh frozen lung 
tumours and adjacent normal tissues from lung 
cancer patients were retrieved from the tissue 
bank of the Thoraxklinik in Heidelberg, 
Germany. Clinical and demographic characteris-
tics of patients included in the study are 
described in Supplementary Table 1. All 
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participants provided written informed consent. 
The study was approved by the Ethics committee 
of the Medical Faculty of the University of 
Heidelberg (Nr. 270/2001).
Risk region definition and sureselect methyl seq 
custom capture library design
Using the PubMed database, the literature was 
screened for studies describing loci associated with 
lung cancer risk from familial cases, case–control 
studies of candidate genes, GWAS and meta- 
analyses. A full description of the custom capture 
library design is shown in the Supplementary 
Material. Shortly, 84 unique lung cancer risk SNPs 
were extracted from selected studies. A total of 54 
candidate regions spanning 12.078Mb were defined 
as regions in linkage disequilibrium (LD) with the 
risk SNPs (Figures 1 & Figures 2a, Supplementary 
Table 3). Coordinates of selected regions were 
uploaded to SureDesign software (Agilent) with 
the following bait tailing parameters: +strand, den-
sity 2x, balanced boosting and most stringent mask-
ing of repetitive elements, centred, length 120bp 
and an allowed overlap of 20bp. After removal of 
34,048 non-CpG containing baits, the custom 
library was composed of 57,676 probes and 
spanned 4.038Mb.
Figure 1. Distribution of minimal differentially methylated regions (MDMRs) in lung cancer risk regions. Nineteen human autosomes 
are depicted with MDMRs distribution in 54 lung cancer risk regions (coordinates are listed in Supplementary Table 3). The 
innermost track depicts the lung cancer risk regions per chromosome in different colours. The second and third tracks depict 
changes in MDMRs DNA methylation in squamous cell carcinoma (SCC) and adenocarcinoma (AD) patients, respectively. Blue 
denotes hypomethylated MDMRs and red denotes hypermethylated MDMRs.
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DNA-targeted enrichment and methylation 
analysis
SureSelectXT MethylSeq (Agilent) was used to 
perform targeted enrichment of selected loci 
according to the manufacturer’s instructions (ver-
sion B January 2013) in the discovery cohort, 
including 11 AD and 13 SCC tumour and adjacent 
normal tissue samples. A complete description of 
the protocol is shown in the Supplementary 
Material. Briefly, the protocol was modified as 
follows: 6 µg of DNA were used as starting mate-
rial and sheared in a 50 µl volume using 
a CovarisS1 instrument with the following settings: 
duty cycle, 10%; intensity, 5; cycles per bust, 200; 
time, 4 cycles of 60 seconds and 1 cycle of 30 sec-
onds; set mode, frequency sweeping and tempera-
ture, 4 to 7°C. Amplification and indexing PCRs of 
the bisulphite-treated libraries (EZ DNA 
Methylation-Gold™ Kit, Zymo Research) were car-
ried out in a LightCycler 480 (Roche) including 1x 
SybrGreen (10,000x, Invitrogen) adjusting PCR 
cycle number when necessary. Libraries were mul-
tiplexed in groups of 12 and sequenced in 
IlluminaHiSeq2000 with 100bp paired-end 
sequencing at DKFZ Genomics and Proteomics 
Core Facility, Heidelberg.
Bisulphite sequencing data analysis
Reads were mapped against two reverse comple-
mentary in-silico bisulphite converted strands of 
the human reference sequence (hg19) using 
methylCtools [16]. First adaptor sequences were 
trimmed using SeqPrep followed by the modifica-
tion of all sequencing reads, such that cytosines 
were masked by thymines and guanines by ade-
nines. Afterwards, the converted reads were 
mapped against the reference sequence using 
BWA-ALN (version 0.6.2) [17] and the non- 
default parameters – q20-s. PCR duplicates were 
removed using PICARD MarkDuplicates. After 
alignment and duplicate removal, sequencing 
reads were translated back into their original 
state and for each CpG position the number of 
methylated (and unmethylated) cytosines was cal-
culated by counting the number of reads showing 
evidence for methylated (and unmethylated) state 
at the guanine position. Reads with a mapping 
quality less than 1 and bases with a PHRED- 
scaled quality less than 20 were discarded. To 
avoid accuracy issues and SNP-induced variability 
in CpG methylation, we only considered on-target 
CpG positions with a sequencing depth greater or 
equal to 20, not overlapping a known SNP from 
dbSNP135 [18]. Of the 71,787 CpGs in the tar-
geted regions, 15,854 CpGs overlapping SNPs were 
excluded from further analysis.
SNP calling within the target regions was per-
formed using the bisulphite conversion aware 
SNP-caller Bis-SNP [19] using the non-standard 
parameters -out_modes 
EMIT_VARIANTS_ONLY -toCoverage1000. To 
enhance the reliability of the called polymorph-
isms, we only considered SNPs known from 
dbSNP135 with a PHRED-scaled confidence 
score greater or equal to 50.
Samples were then subjected to quality control 
and excluded from further analysis if: median 
on-target CpG coverage <14x or estimated bisul-
phite conversion efficiency <96.5%. Mean bisul-
phite conversion efficiency per sample was 
estimated as 1 – the mean chromosomal methy-
lation in non-CpG sites (mCH). Only SNP posi-
tions which were consistently covered by more 
than 9 reads among all individuals were consid-
ered. Seven samples were excluded after quality 
control giving rise to the drop of 7 tumour/ 
normal tissue pairs and leaving 17 pairs for 
further analysis.
Differentially methylated positions (DMPs) 
were calculated with the R-package methylKit 
[20] using the following criteria: minimum 
sequencing depth at CpG positions of 20x, methy-
lation difference between tumour and normal tis-
sue samples ≥10% and Fisher’s exact test 
p-value≤0.05. Differentially methylated regions 
(DMRs) were called with the R-package eDMR 
[21] using the following criteria: DMP methylation 
difference ≥10%, q-value≤0.05, minimum of 3 
DMPs in the same direction, distance between 
neighbouring CpGs ≤300bp, DMR methylation 
difference ≥10% and q-value <0.05. For both 
DMP and DMR analysis, we performed multiple 
testing correction using a Benjamini-Hochberg 
approach that controls for false discovery rate 
(FDR). DMRs were not identical in all patients 
but rather they tended to overlap with different 
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ends. Thus, in order to focus on the most impor-
tant deregulated regions, we defined Minimal 
Differentially Methylated Regions (MDMRs), i.e., 
regions where a DMR occurred in more than 50% 
of the patients.
Further description of methods regarding 
enrichment analysis and TCGA data analysis as 
well as description of MassArray Epityper and 
dual-luciferase assays are provided in 
Supplementary Materials.
Results
Targeted enrichment of lung cancer candidate 
DNA regions
Our aim to study comprehensively the epigenetic 
changes occurring in lung cancer risk regions 
required a different approach to those commonly 
being applied for DNA methylation analysis, such 
as Illumina450K or MeDiPseq, as these would not 
properly cover our regions of interest. From the 
literature, we defined 54 lung cancer candidate 
deregulated regions spanning a total of 12,078 
Mb (Figure 1, Supplementary Table 3). In order 
to establish DNA methylation profiles in these 
regions, we designed a custom capture library to 
enrich for genomic DNAs covering the selected 
sequences. Library design is summarized in 
Figure 2a. Briefly, the initial 91.950 probes of the 
SureSelect DNA library (Agilent) covering all 54 
candidate regions were narrowed down by remov-
ing non-CpG containing baits and repetitive 
sequences. The final custom capture library con-
sisted of 57,676 probes spanning 4.038Mb and 
covering a total of 71,787 CpG dinucleotides of 
which 22.3% are located in promoter regions 
(defined as 2Kb upstream and 1 Kb downstream 
of the TSS), 4.3% in 5´UTR, 23% in exons, 50.2% 
in introns, 2.4% in 3´UTR, and 28.8% in intergenic 
regions (Figure 2b). The number of captured CpGs 
per targeted region is shown in Supplementary 
Table 3.
For the DNA methylation analysis, we isolated 
DNA from lung tumour tissue and adjacent nor-
mal tissue from lung cancer patients. The clinical 
and demographic characteristics of patients 
included in the discovery cohort are listed in 
Supplementary Table 1. DNA samples were 
enriched for our candidate regions, sodium bisul-
phite converted and then analysed by next- 
generation sequencing. After applying quality 
standards described in the methods section, we 
analysed methylation patterns of 17 patients 
including 7 AD and 10 SCC matched tumour- 
normal tissue pairs. Bisulphite sequencing data 
for samples that passed the quality control had 
a median of 10.88 million analysable reads and 
a median read depth at on-target CpGs of 127x. 
The median on-target reads-ratio of 91.6% indi-
cated a high level of enrichment for the targeted 
regions that also showed high conversion effi-
ciency (median bisulphite conversion efficiency 
of 98.9%).
DNA methylation analysis identifies differences 
in the DMRs from AD and SCC
DNA methylation analysis of the risk regions 
revealed lower methylation levels in tumour tis-
sues in comparison to the adjacent normal tissue 
(median of the median methylation per sample 
71.67% and 78.6% in tumour and normal tissue, 
respectively). Broad DNA methylation patterns in 
the targeted regions are shown in Supplementary 
Materials, Supplementary Figure 1. Interestingly, 
the median methylation for lung AD samples was 
75.6%, closer to the methylation levels found in 
normal tissue (78.6%) than to the ones found in 
lung SCCs (63.78%) (Figure 2c). Unsupervised 
hierarchical clustering of the 5,000 most variable 
CpGs showed 3 clusters of samples corresponding 
to the normal tissues, AD and SCC samples 
(Figure 2d) revealing that methylation patterns in 
the analysed regions were globally disturbed in the 
tumours in comparison to normal tissue, but also 
differed significantly between tumour subtypes.
In order to validate our results, we compared 
our data with publicly available Illumina 450 K 
methylation data of lung adenocarcinoma 
(LUAD) and lung squamous cell carcinoma 
(LUSC) from The Cancer Genome Atlas (TCGA) 
and we implemented a high-throughput technol-
ogy for replication of our results (Supplementary 
Material, Supplementary Figure 3).
To exclude inter-individual differences from the 
analyses, we analysed intrapair methylation 
changes for the tumour and normal tissue 
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matched samples. We detected a median of 16,706 
differentially methylated positions (DMPs) in SCC 
tumour-normal pairs, consisting of a median of 
12,517 hypomethylated DMPs and 3,419 hyper-
methylated DMPs, with a median methylation dif-
ference between tumour and normal tissue of 
−28,69% and 21.16%, respectively. For AD tissue 
pairs, we detected a median of 7,259 DMPs com-
prising 2,757 hypomethylated and 2,741 hyper-
methylated DMPs, with a median methylation 
difference of −18.93% and 18.27%, respectively. 
The number of DMPs per patient is shown in 
Supplementary Table 4.
We extended our methylation analysis to 
identify differentially methylated regions 
(DMRs) between tumour and normal tissue 
samples. We found a median of 1,086 DMRs 
among SCC patients (median of 937.5 hypo- 
and 124 hypermethylated) and 350 DMRs 
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Figure 2. Scheme for custom capture library and results from overall methylation analysis. (A) Workflow for custom capture library 
design. (B) Distribution of capture baits in genomic regions. (C) Violin plot depicting distribution of methylation levels and median 
values per sample. (D) Heatmap depicting the unsupervised hierarchical clustering of 5,000 most variable CpG sites between 17 
tumour and adjacent normal tissue samples. Sample type is colour coded as follows: normal samples in grey, lung adenocarcinoma 
(AD) samples in yellow and lung squamous cell carcinoma (SCC) samples in green.
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and 59 hypermethylated). In both tumour 
subtypes hypomethylated DMRs were predo-
minant, with a median frequency of 90.6% in 
SCC and 52.1% in AD; however, AD patients 
had a bigger proportion of hypermethylated 
DMRs compared to SCC patients (Figure 3a). 
The number of hyper- and hypomethylated 
DMRs per subject is shown in 
Figure 3. Differentially methylated regions (DMRs) and DMR enrichment analyses. (A) Proportion of hyper- (in red) and hypomethy-
lated DMRs (in blue) from pairwise tumour-normal comparison per subject. (B) DMRs enrichment analysis by genomic location using 
RefSeq annotation. Left hypermethylated, right hypomethylated DMRs. (C) DMRs enrichment analysis in chromatin states from lung 
tissue using 15-states ChromHMM definition from roadmap epigenomics consortium data. Dots depict significant enrichments 
(p-value < 0.01 and fold change > 2 or <0.5). Left hypermethylated, right hypomethylated DMRs. Sample type is colour coded as 
follows: adenocarcinoma (AD) samples in yellow and squamous cell carcinoma (SCC) samples in green.
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Supplementary Table 4. For the complete list 
of DMRs per patient, including p-values, see 
Supplementary Table 5.
The median CpG content of DMRs was 6 in 
both tumour subtypes, and the median length 
was slightly longer in AD compared to SCC 
patients (431bp vs. 401.75bp, respectively). In 
accordance with the DMPs data, methylation 
difference of DMRs was smaller in AD than in 
SCC, with a mean DMR methylation difference 
per patient of 18.3% and 24.8% in AD and SCC, 
respectively.
To understand the genomic localization of the 
DMRs, we performed an enrichment analysis of 
DMRs in genomic locations using RefSeq gene 
annotation. Additionally, in order to examine 
their possible influence on gene expression or in 
the activity of regulatory elements, we analysed 
their enrichment in lung tissue chromatin states 
(15-states of ChromHMM) defined by their 
deposition of different histone marks (Roadmap 
Epigenomics Consortium) [22] (Figures 3b and 
c). 8-ZNF/Rpts chromatin state (ZNF genes & 
repeats), including repetitive elements, was not 
analysed as those regions had been specifically 
excluded from our library, thus keeping 14- 
states for the analysis. Enrichment was consid-
ered when at least 50% of the patients (4 of 
7 AD subjects and 5 of 10 SCC subjects) showed 
a p-value ≤0.01 and fold change >2 or <0.5 for 
a certain region of interest. Interestingly, the 
genomic localization of hyper- and hypomethy-
lated DMRs was different. SCC and AD hyper-
methylated DMRs were enriched in CpG islands 
(CGI), CGI shores and exons. In addition, 5 SCCs 
showed an enrichment of DMRs in 3ʹUTRs. On 
the other hand, for hypomethylated DMRs, no 
major enrichment was observed, but they are 
depleted in CGI shores for AD (4/7 subjects) 
(Figure 3b). The analysis of the distribution of 
hypermethylated DMRs in the 14 lung chromatin 
states showed a depletion of DMRs in the 
Quiescent State (Quies) for 6 out of 10 SCC 
patients and enrichment for both AD and SCC 
subjects in the repressive states Bivalent 
Enhancer and Repressed by Polycomb (EnhBiv 
and ReprPC) and also in active regulatory enhan-
cer states (Enh and EnhG) (Figure 3c). Similarly 
to the results observed in the enrichment in 
genomic locations, hypomethylated DMRs did 
not show major enrichments, but depletions were 
found in SCC for DMRs in the active states 
Strong transcription and Flanking active TSS 
(Tx and TssA) for 9 out of 10 individuals.
Validation and replication of top deregulated 
regions
In order to focus on the most interesting deregu-
lated regions, we extracted the minimal differen-
tially methylated regions (MDMRs) defined as 
regions where a DMR occurred in the same 
direction in more than 50% of the patients 
(Figure 4a). A full list of the MDMRs and 
descriptive statistics is provided in 
Supplementary Table 6. We found 1,102 
MDMRs for SCC (94.5% hypomethylated and 
5.5% hypermethylated) and 80 MDMRs for AD 
(57.5% hypomethylated and 42.5% hypermethy-
lated). The number of MDMRs per targeted 
region is shown in Figure 1 and Supplementary 
Table 3. To gain an overview of the methylation 
differences between both tumour subtypes we 
evaluated the number of overlapping MDMRs 
(Figure 4a). We found 59 MDMRs in both AD 
and SCC datasets, of which 17 were hypermethy-
lated. Two MDMRs were hypermethylated in AD 
and hypomethylated in SCC indicating their 
putative different roles in tumour subtypes, and 
40 hypomethylated MDMRs were defined with 
the exact same coordinates in both tumour sub-
types giving rise to a total number of identified 
unique MDMRs of 1,142. The median CpG con-
tent of MDMRs was 13.92 in SCC and 12.56 
in AD, and the median length was slightly longer 
in AD compared to SCC, similar to the previous 
finding for DMRs (408bp vs. 402bp). In addition, 
in both tumour subtypes hypermethylated 
MDMRs were longer than hypomethylated ones 
(AD: 489bp vs. 359.5bp and SCC: 600bp vs. 
398bp). The mean methylation difference per 
MDMR was −24.46% and 19.3% for SCC hypo- 
and hypermethylated MDMRs, and a little smaller 
for AD MDMRs, with −16.05% and 16.4%, 
respectively.
We compared our data with LUAD and LUSC 
datasets from TCGA and found that 85.8% of 
the identified MDMRs would be missed in 450 K 
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data while the biggest proportion of the captured 
MDMRs would be covered only by 1 probe. 
After data normalization and quality control, 
only probes covering 140 MDMRs were kept. 
The absolute mean MDMR methylation differ-
ence with our approach was 21.4% while the 
TCGA mean methylation difference was only 
4.53%. These data illustrate the poor coverage 
of 450 K in the most interesting regions revealed 
by our analysis within lung cancer risk regions, 
and indicate that most studies will have probably 
missed those methylation changes.
Furthermore, we analysed the distribution of 
MDMRs in 14 different ChromHMM states from 
lung tissue (Figure 4c). Interestingly, we found an 
enrichment of hypermethylated MDMRs in repres-
sive chromatin states from lung tissue, such as 
Bivalent Enhancer and Repressed by Polycomb, and 
in the active enhancer states, with a fold change higher 
than 3 and p-value <0.05. For hypomethylated 
MDMRs we did not find major enrichments (Figure 
4c). We also evaluated the location of transcription 
factor motifs from HOCOMOCO database among 
the MDMRs. A full list of all transcription factor 
motifs for each tumour type is reported in 
Supplementary Table 8. Briefly, we found an enrich-
ment of Fos family members and Jun in AD hypo-
methylated MDMRs that have been implicated as 
regulators of cell proliferation, differentiation and 
transformation (Supplementary Materials, 
Supplementary Figure 5B). Importantly, Sp subfamily 
members are enriched in all four MDMR sets (AD 
and SCC, hyper- and hypomethylated) 
(Supplementary Materials, Supplementary Figure 5). 
This subfamily has been described as potential activa-
tors or repressors of expression in different promo-
ters. Other relevant transcription factor motifs 
involved in apoptosis, DNA replication, and carcino-
genesis have also been found enriched in the MDMRs 
(Supplementary Materials, Supplementary Figure 5).
Figure 4. Identification of minimal differentially methylated regions (MDMRs) and MDMR enrichment analyses. (A) Scheme of MDMR 
annotation. MDMRs are defined as the regions where, within at least one tumour subtype, DMRs overlap in more than 50% of the 
subjects. (B) Venn diagram showing the number of overlapping MDMRs between hyper- and hypomethylated MDMRs in squamous 
cell carcinoma (SCC) and adenocarcinoma (AD). (C) Enrichment of hypomethylated (left) and hypermethylated (right) MDMRs in 
chromatin states from lung tissue using 15-states ChromHMM definitions.
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Validation and replication of selected MDMRs
For candidate selection, we ranked the MDMRs 
according to their absolute mean methylation dif-
ference among AD or SCC patients. MDMR 
enrichment in ChromHMM states indicated 
a putative role of the MDMRs in the deregulation 
of regulatory elements. Thus, we selected a total of 
7 MDMRs from the top 15 in each tumour subtype 
to test their potential role as regulatory elements 
(Supplementary Table 2). Three MDMRs were 
selected from the SCC list, including 1 hyper-
methylated MDMR (MDMR_1) and 2 hypomethy-
lated ones (MDMR_5 and MDMR_7). For AD 4 
MDMRs were selected comprising 3 hypermethy-
lated MDMRs (MDMR_2, MDMR_3 and 
MDMR_6) and MDMR_4 which is hypomethy-
lated in the tumours. MDMR_1 was located on 
chromosome 3, in the intron of Xyloside 
Xylosyltransferase 1 Antisense RNA 2 (XXYLT1- 
AS2), a non-coding RNA that overlaps with the 
3rd intron of XXYLT1. MDMR_1 showed 
a methylation difference of 42.50% between 
tumour and normal tissue and contains 11 CpGs. 
MDMR_2 and MDMR_3 are in the CDKN2B- 
CDKN2A gene cluster on chromosome 9p21 
located in the 1st intron of the Cyclin Dependent 
Kinase Inhibitor 2A (CDKN2A) and the CDKN2B 
Antisense RNA 1 (CDKN2B-AS1) with a difference 
in methylation of 23.6% and 21.5%, respectively. 
MDMR_4 showed a difference in methylation of 
−25.2% and it is located on chromosome 13 in the 
18th intron of Mitochondrial Intermediate 
Peptidase (MIPEP) gene. MDMR_5 located on 
chromosome 18, in intron 2 of Piezo Type 
Mechanosensitive Ion Channel Component 2 
(PIEZO2) exhibited a hypomethylation of 
−48.42%. MDMR_6 is located in intron 3 of the 
Nuclear Factor Of Activated T-Cells 2 (NFATC2) 
on chromosome 20 and showed a difference in 
methylation of 27.3%. Finally, MDMR_7 is located 
in the 3 UTR of the HORMA Domain Containing 
2 (HORMAD2) gene on chromosome 22 and 
showed a difference in methylation of −38.4%.
We validated all MDMR results from the dis-
covery sample set by MassArray Epityper assay 
(Agena Bioscience) using primers listed in 
Supplementary Table 7. A candidate MDMR was 
considered as technically validated when in the 
same tumour-subtype, the mean methylation dif-
ference was >20%, in the same direction as 
reported in the discovery cohort and the p-value 
<0.05. Thereby, all MDMRs from the discovery 
sample set were validated (Figure 5a). Next, 
MDMRs were replicated in 2 larger independent 
lung cancer cohorts. Clinical and demographic 
characteristics of the patients included in both 
replication cohorts are presented in 
Supplementary Table 1. First, an independent 
cohort comprised by 14 AD and 13 SCC patients 
with the same characteristics as the discovery 
cohort (Replication cohort 1) was used to replicate 
our findings for the 7 MDMRs by MassArray 
(Figure 5b). Then, a larger cohort of 44 AD and 
43 SCC patients (Replication cohort 2), compris-
ing both male and female subjects as well as dif-
ferent lung cancer stages ranging from IA to IIIA 
was used to replicate our results in a more com-
prehensive lung cancer cohort (Supplementary 
Table 1, Figure 5c). All candidate MDMR methy-
lation values were replicated in both cohorts indi-
cating the general deregulation of the candidate 
regions in lung cancer.
Evidence from in vitro assays for regulatory 
activity of selected MDMRs
To confirm the role of the candidate MDMRs as 
regulatory elements that are aberrantly methylated 
in lung cancer, we used a dual-luciferase reporter 
assay. Both the plus and minus strands of the 
candidate MDMRs were cloned into the reporter 
firefly constructs pGL4.10 and pGL4.23, to test 
their role as promoter and enhancer regulatory 
elements. Six out of the 7 tested regions showed 
regulatory activity (Figure 6a). MDMR_3 within 
CDKN2B-AS1 did not show any potential as reg-
ulatory element under the experimental conditions 
tested. MDMR_1 in XXYLT1-AS2 seemed to have 
both promoter and enhancer activity in both DNA 
strands. Three MDMRs at CDKN2A, MIPEP, and 
NFATC2 (MDMR_2, MDMR_4, and MDMR_6, 
respectively) showed both promoter and enhancer 
activity in the plus strand, and MDMRs located 
within PIEZO2 and HORMAD2 (MDMR_5 and 
MDMR_7) showed both promoter and enhancer 
activity in the minus strand. Collectively, these 
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in vitro data confirm that among 7 identified 
MDMRs, only MDMR_3 displayed no potential 
as a regulatory region.
Next, we investigated the possible role of DNA 
methylation in the regulatory activity of candidate 
promoters and enhancers within the identified 
MDMRs using the pCpG-free-promoter Lucia vector 
as a reporter. Based on the regulatory activity deter-
mined in the previous experiment, candidate regions 
were cloned in forward or reversed directions. In line 
with previous results, we found that all candidate 
regions except for the MDMR_1 at CDKN2B-AS1 
showed overexpression of the reporter when they 
were un-methylated (Figure 6b). This indicates that 
DNA methylation at candidate MDMRs may contri-
bute to a change in the regulatory activity of these 
regions which could be affecting the expression of 
genes and non-coding RNAs, possibly, but not neces-
sarily, in the vicinity, with a potential role in the 
initiation or progression of lung cancer.
Discussion
Throughout the last decades, GWAS have led to the 
discovery of lung cancer risk SNPs that are associated 
with disease susceptibility or its progression. However, 
Figure 5. (A) Candidate MDMRs DNA methylation in the discovery cohort validated by MassArray epityper assay. (B) Replication of 
candidate MDMRs in the replication cohort 1 by MassArray. (C) Replication of candidate MDMRs in the replication cohort 2 by 
MassArray. * p-value < 0.05. ** p-value <0.005. *** p-value < 0.0005. Whiskers indicate 5–95% percentiles.
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the causative variants for these associations and the 
genes or regulatory elements playing a central role in 
lung carcinogenesis are still far from being completely 
understood. Today, we are able to study the methy-
lome as a marker of epigenetic changes that may 
contribute to lung cancer. With the aim of expanding 
Figure 6. In vitro analysis of promoter and enhancer function, and effect of methylation on regulatory activity. (A) Bar plot of the 
dual-luciferase assay in HEK293T cell line to test promoter and enhancer regulatory effect of candidate MDMRs on both the plus (+) 
and minus (-) strand. (B) Bar plot of the dual-luciferase assay to test the effect of DNA methylation on the regulatory activity of 
candidate MDMRs in HEK293T cells. * p-value < 0.05. ** p-value <0.005. *** p-value < 0.0005. Error bars represent standard 
deviation.
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the understanding of lung cancer and of identifying 
new causative regulatory regions for the known asso-
ciations, we investigated DNA methylation changes in 
previously described lung cancer risk regions. We 
conducted methylation analysis by targeted DNA 
bisulphite sequencing and demonstrated the power 
of this approach to detect aberrantly methylated loci 
previously overlooked by other approaches. The com-
parison of methylation patterns of lung tumour and 
matched normal tissues as basis for the identification 
of differentially methylated positions allowed us to 
focus on lung cancer-specific methylation alterations, 
i.e., discarding interindividual methylome 
heterogeneity.
We detected a large number of DNA methyla-
tion changes occurring in SCC and AD lung can-
cer subtypes within the defined lung cancer risk 
regions. Both tumour entities showed global hypo-
methylation when compared with the normal sam-
ples, in line with previously described data for 
cancer tissues [23]. However, we found that for 
the defined lung cancer risk regions AD accumu-
lated fewer methylation aberrations and thus 
resembles normal tissue more closely than SCC. 
Although our targeted approach covered only 
a small portion of the genome, our DNA methyla-
tion data allowed for discrimination of 3 clusters 
of samples (Normal, AD tumour, and SCC tumour 
tissues). The two lung cancer subtypes investigated 
showed different methylation profiles in the lung 
cancer risk regions, which could be due to the 
different origin and evolution of the tumour enti-
ties, but may also be related to the definition of the 
risk regions.
The present study provides a comprehensive 
list of differentially methylated regions detected 
in the different AD and SCC patients that can be 
used as a resource to identify links between risk 
SNPs and the underlying molecular cause of dis-
ease. In order to focus on the most interesting 
deregulated regions and to provide functional 
characterization for some candidates, we com-
bined the DMRs of the different subjects into 
MDMRs. We found a different distribution of 
hyper- and hypomethylated MDMRs in genomic 
regions and ChromHMM states indicating differ-
ences in their behaviour and a role in lung cancer. 
Interestingly, we found an enrichment of 
MDMRs in regulatory elements such as 
enhancers. Our results are in line with those 
from Shi et al., who found enrichment of 
meQTLs in regulatory regions analysed in 
TCGA datasets [11]. Thus, we tested the role of 
7 MDMRs as putative regulatory elements. Of 
these, 6 MDMRs showed regulatory activity, 
with their effects occurring mostly when DNA 
was not methylated. Taken together, these results 
confirm the potential of the MDMRs as methyla-
tion-dependent regulatory regions that can con-
tribute to lung cancer initiation and/or 
progression.
One of the selected candidates, XXYLT1-AS2, is 
an antisense-RNA of the XXYLT1 gene. XXYLT1 
has been implicated in the cancer-related Notch 
pathway as a regulatory gene product of the Notch 
receptor activation [24]. A role of anti-sense RNAs 
in the regulation of gene expression has previously 
been described [25]. MDMR_1 might affect both 
the expression of XXYLT1-AS2 and XXYLT1. 
MDMR_4 is located in the intron of MIPEP gene 
that has been reported as a modulator of Notch 
activity. Both MDMRs could alter the Notch path-
way, with effects in cancer cell signalling.
Different regions from the gene cluster 
CDKN2A-CDKN2B have been implicated in can-
cer and in particular in lung cancer. In our analy-
sis, several DMRs were defined in this gene cluster, 
summarized in several MDMRs, with two of them 
highly ranked among our candidates (MDMR_2 
and MDMR_3). MDMR_3 located in the 
CDKN2B-AS1 did not show regulatory potential 
under the tested conditions which does not, how-
ever, exclude a possible regulatory activity in lung 
cells.
The PIEZO2 gene could be under the regulation 
of MDMR_5. This gene is a pseudogene of 
PIEZO1 (FAM38A) which has been associated 
with a reduction of cell adhesion and an increase 
in cell migration in small cell lung cancer [26]. In 
addition, PIEZO1 has been postulated as a good 
candidate for diagnosing gastric cancer [27]. We 
hypothesize that PIEZO2 might play a central role 
in lung cancer. MDMR_6 might be involved in 
regulation of the NFATC2 gene. NFATC2 is 
a DNA-binding protein that is present in the cyto-
sol and translocates to the nucleus upon T-cell 
receptor activation. NFATC2 has a key role in 
immune response by inducing gene transcription. 
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However, NFAT isoforms present in the tumour 
microenvironment also contribute to the regula-
tion of the interactions between compartments 
and have a function in cell growth, survival, inva-
sion, differentiation, proliferation and angiogen-
esis [28–31]. NFATC2 has been shown to be pro- 
invasive and pro-migratory in breast carcinoma 
[32,33].
MDMR_7 at the HORMAD2 locus also showed 
a potential regulatory effect. HORMAD2 is predo-
minantly expressed in human testis; however, it is 
ectopically expressed in nearly 10% of lung cancer 
samples from Chinese Han individuals [34].
We acknowledge the limited power of our 
study due to the small sample size in the dis-
covery cohort that could potentially limit the 
number of identified deregulated regions. 
However, samples were selected as homogenous 
as possible to limit the effect of confounding 
factors. Furthermore, some candidates were vali-
dated in 2 independent cohorts, including 
a heterogeneous larger one, indicating the relia-
bility of our results. There are a variety of 
mechanisms by which SNPs can affect methyla-
tion (reviewed in Wang et al. [35]). 
Unfortunately, the limited number of samples 
and the design of the custom library (which 
resulted in the capture of a unique strand thus 
preventing discrimination between methylation 
status of the CpG or the C/T alleles of an over-
lapping SNP) did not allow us to analyse the 
connection between DNA methylation alteration 
and genetic variants. However, we were able to 
narrow down lung cancer risk loci to the most 
interesting deregulated regions that can be 
further investigated to decipher their role in 
lung carcinogenesis.
The MDMRs we studied in vitro pointed us 
towards candidate genes that have a putative role 
in the molecular mechanisms of lung tumour 
initiation or progression as denoted by the path-
ways affected, their interactions with cancer- 
related genes or their previously described role 
in other cancer types. Thus, these candidates 
and the MDMR associated loci need to be inves-
tigated in depth in further studies, which consider 
their functional effects, including a potential 
impact on chromatin structure in distant regula-
tory regions.
Conclusions
This is the first study that comprehensively 
explored DNA methylation patterns at single 
CpG resolution at the GWAS-identified lung can-
cer risk loci. Aberrantly methylated regions in 
tumour tissue were identified, and an enrichment 
of differentially methylated regions in regulatory 
elements was shown. Furthermore, in vitro func-
tional assays demonstrated a methylation- 
dependent enhancer activity for 6 out of 7 tested 
MDMRs. Taken together, these results confirm the 
potential of the MDMR regions as methylation- 
dependent regulatory elements that can contribute 
to lung cancer initiation and/or progression. The 
data presented here will be very valuable to under-
stand the pathways implicated in lung cancer and 
provide new targets for further functional charac-
terization as potential druggable targets for cancer 
treatment.
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